Zobrazeno 1 - 10
of 49
pro vyhledávání: ''
Autor:
Paul L. Martin, Carl H. June, Henrique Bittencourt, Hidefumi Hiramatsu, G.D. Myers, Michael A. Pulsipher, Kapildeb Sen, Kara L. Davis, S. Rives, Michael R. Verneris, Yiyun Zhang, Gregory A. Yanik, David Lebwohl, Shannon L. Maude, Jochen Buechner, Christina Peters, Nicolas Boissel, Adriana Balduzzi, B. De Moerloose, Tanya Taran, Stephan A. Grupp, Krysta Schlis, Karen Thudium Mueller, Peter Bader, Michael Boyer, Mimi Leung, Muna Qayed, André Baruchel, Theodore W. Laetsch, Joerg Krueger, Bruce L. Levine, Patricia A. Wood, Heather E. Stefanski, Eneida R. Nemecek, Francoise Mechinaud
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children a
Autor:
Anne Chew, David M. Barrett, Yolanda D. Mahnke, Bruce L. Levine, Noelle Frey, David L. Porter, Pamela A. Shaw, J. Joseph Melenhorst, Carl H. June, Zhaohui Zheng, Susan R. Rheingold, Nancy Bunin, Shannon L. Maude, Vanessa E. Gonzalez, David T. Teachey, Stephan A. Grupp, Simon F. Lacey, Angela Shen, Richard Aplenc
Publikováno v:
New England Journal of Medicine. 371:1507-1517
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission
Autor:
Khaled M. Musallam, Ali T. Taher
Publikováno v:
New England Journal of Medicine. 364:146-156
A 16-year-old boy with sickle cell anemia undergoes routine screening with transcranial Doppler ultrasonography to assess the risk of stroke. This examination shows an abnormally elevated blood-flow velocity in the middle cerebral artery. The hemoglo
Autor:
Saglio, G, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Alimena, Giuliana, Larson, Ra, Kantarjian, Hm, Enestnd, Investigators
Publikováno v:
New England Journal of Medicine. 362:2251-2259
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome–positive chronic myel
Autor:
Giovannoni, G, Comi, G, Cook, S, Rammohan, K, Rieckmann, P, Soelberg Sørensen, P, Vermersch, P, Sandberg Wollheim, M, Cuzick, J, Juliusson, G, Reingold, S, King, J, Pollard, J, Sedal, L, Aichner, F, Eggers, C, Dive, D, Medaer, R, Ferreira, M, Manchev, I, Milanov, I, Haralanov, L, Deleva, N, Petrova, N, Bozhinov, P, Zahariev, Z, Stamenov, B, Shotekov, P, Petrov, I, Moskov, R, Emond, F, Freedman, M, Grand'Maison, F, Jacques, F, Vorobeychik, G, Demarin, V, Kovacicek, M, Lusic, I, Perhat Bucevic, T, Havrdova, E, Talab, R, Kanovsky, P, Petersen, T, Gross Paju, K, Kalbe, I, Toomsoo, T, Elovaara, I, Eralinna, Jp, Reunanen, M, Clavelou, P, Damier, P, Debouverie, M, Edan, G, Gout, O, Labauge, P, Laplaud, D, Wiertlewski, S, Heidenreich, F, Mäurer, M, Kieseier, B, Limmroth, V, Oschmann, P, Schimrigk, S, Steinbrecher, A, Zettl, U, Ziemann, U, Karageorgiou, K, Kyritsis, A, Papadimitriou, A, Amato, Mp, Bernardi, G, Morra, Vb, Galgani, S, Gallo, Paolo, Patti, F, Marrosu, M, Pozzilli, C, Trojano, M, Mancardi, Gl, Gebeily, S, Koussa, S, Wehbe, M, Yamout, B, Vaitkus, A, Metra, M, Messouak, O, Mossaddaq, R, Slassi, I, Yahyaoui, M, Hupperts, Rm, Czlonkowska, A, Kozubski, W, Nyka, W, Selmaj, K, Szczudlik, A, Figueiredo, J, Pedrosa, R, Alifirova, V, Balyazin, V, Barbarash, O, Belova, A, Boyko, A, Gusev, E, Elchaninov, A, Jacoupov, E, Julev, N, Kotov, S, Kudryavtsev, A, Laskov, V, Lesnyak, O, Odinak, M, Pasechnik, E, Poverennonva, I, Skoromets, A, Spirin, N, Stolyarov, I, Vorobieva, O, Voskresenskaya, O, Zaslavskiy, L, Zonova, E, Bohlega, S, El Jumah, M, Drulovic, J, Nadj, C, Goebels, N, Schluep, M, Ayed Frih, M, Hentati, F, Mhiri, C, Mrabet, A, Mrissa, R, Idiman, E, Karabudak, R, Turan, Of, Ahmed, F, Constantinescu, C, Hawkins, C, Palace, J, Sharrack, B, Loganovsky, K, Moskovko, S, Nehrych, T, Voloshyna, Np, Carlini, W, English, J, Garmany, G, Glyman, S, Huddlestone, J, Hurwitz, B, Kresa Reahl, K, Mikol, D, Pardo, G, Rao, H, Reif, M, Thrower, B, Royal, W, Webb, R, Wynn, D, Naga, C, Allen, N, Lin, K, Stefoski, D, Balabanov, R.
Publikováno v:
New England Journal of Medicine, 362(5), 416-426. MASSACHUSETTS MEDICAL SOCIETY
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing–remitting multiple sclerosis. We randomly ass
Autor:
Philip Raskin, Darrell M. Wilson, Peter A. Gottlieb, Robin Goland, Diane K. Wherrett, Desmond A. Schatz, Carla J. Greenbaum, Jay S. Skyler, Stephen E. Gitelman, Dorothy J. Becker, John M. Lachin, Paula McGee, Henry Rodriguez, Jennifer B. Marks, Mark D. Pescovitz, Antoinette Moran, Heidi Krause-Steinrauf
Publikováno v:
New England Journal of Medicine. 361:2143-2152
BACKGROUND: The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte–mediated diseases. It is possible to achieve selecti
Autor:
Martin S. Tallman, Mark R. Litzow, Selina M. Luger, Zhuoxin Sun, Hillard M. Lazarus, Gordon W. Dewald, Jacob M. Rowe, Rhett P. Ketterling, Hugo F. Fernandez, Xiaopan Yao, Elisabeth Paietta, John M. Bennett, Janis Racevskis
Publikováno v:
New England Journal of Medicine. 361:1249-1259
In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. We evaluated the use of cytarabine plus either standard-dos
Autor:
Liesl Page-Shipp, Jenny Allen, Paul Meyvisch, Karel de Beule, Alexander S. Pym, Rene Krause, Andreas H. Diacon, Johan Verbeeck, Koen Andries, Martin P. Grobusch, Roxana Rustomjee, Nacer Lounis, Rolf van Heeswijk, R. F. Patientia, Juan Carlos Palomino, Christoffel Pistorius, Amour Venter, David F Mc Neeley, Tine De Marez, Wim Parys, Gavin J. Churchyard, Mampedi Bogoshi
Publikováno v:
The New England journal of medicine
New England journal of medicine, 360(23), 2397-2405. Massachussetts Medical Society
New England journal of medicine, 360(23), 2397-2405. Massachussetts Medical Society
Background The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal ac
Autor:
David Margolin, Camms Investigators, Alasdair Coles, D Alastair S Compston, Kim Norris, Krzysztof Selmaj, P K Tandon, Susan Moran, Stephen Lake
Publikováno v:
New England Journal of Medicine. 359:1786-1801
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitt
Autor:
Orah S. Platt
Publikováno v:
New England Journal of Medicine. 358:1362-1369
An 18-year-old woman with sickle cell anemia presents with recurrent painful crises, and treatment with hydroxyurea is recommended. Hydroxyurea causes a shift toward the production of red cells containing fetal hemoglobin. A possible increase in the